Parents & Educators
National Institute on Drug Abuse – Find the latest science-based information about the health effects and consequences of drug abuse and addiction and resources for talking with kids about the impact of drug use on health.
Entries by malford
Medicines to Keep Addiction Away
The New York Times – America’s drug crisis now kills more people each day than car crashes or gun violence and has challenged the conventional wisdom about recovery. This week we’re discussing another idea whose time has past: trying to kick opioid addiction without medicines. That’s as smart as relying on willpower to overcome diabetes or asthma. Medicines greatly increase the chance of successfully kicking addiction and reduce the risk of death.
Embera NeuroTherapeutics Announces Successful Completion of Phase 1 Clinical Trial Testing EMB-001, a Potential Novel Treatment for Addictions
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine use disorder, smoking cessation, and other addictions, today announced that EMB-001 met the primary endpoints of safety and tolerability in a Phase 1 clinical trial. Embera also announced that the Company’s Chief Executive Officer, Robert Linke and Chief Medical Officer, Dr. Michael Detke, will present at the Biotech Showcase on Monday, January 11, 2016 at 2:30pm in San Francisco, California.
Embera NeuroTherapeutics Initiates Phase 1 Clinical Trial to Test EMB-001 as a Novel Treatment for Addictions
Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of the FDA-approved drugs metyrapone and oxazepam, EMB-001 is being investigated for the potential treatment of cocaine use disorder and other addictions such as tobacco and methamphetamine use disorders.
Embera NeuroTherapeutics Secures A-2 Financing to Advance EMB-001 for Addictions Through Phase 1 Clinical Trial
Embera NeuroTherapeutics, Inc., a specialty biopharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced that it raised $1.9 million in Series A-2 financing. The funding enables the Company to complete a Phase 1, combined single and multiple rising dose clinical trial evaluating the safety and pharmacokinetics of EMB-001 in volunteers who smoke cigarettes but are otherwise healthy.
Embera TechNation Smoking Cessation
Listen to the 2/18/14 episode of BioTech Nation with host Dr. Moira Gunn. Robert Linke, Embera’s CEO, discusses EMB-001 and smoking cessation.
Letter From the Director of the National Institute on Drug Abuse
National Institute on Drug Abuse – Tobacco use kills approximately 440,000 Americans each year, with one in every five U.S. deaths the result of smoking. Smoking harms nearly every organ in the body, causes many diseases, and compromises smokers’ health in general. Nicotine, a component of tobacco, is the primary reason that tobacco is addictive.
Embera Compound Takes New Addiction Treatment Tack
Addictive behaviors – from tobacco use to eating disorders – are among the most difficult to treat and the least likely to result in permanent recovery. That’s precisely why Embera NeuroTherapeutics Inc. is excited about prospects for its EMB-001 . Rather than seeking to block the effects of an addictive substance or substitute a safer compound, the firm’s drug combination suppresses the craving that drives addiction.